Benzinga | Feb 25, 2021 04:01PM EST

Cytokinetics Q4 EPS $(0.62) Down From $(0.52) YoY, Sales $6.72M Miss $8.56M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(0.62) per share. This is a 19.23 percent decrease over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $6.72 million which missed the analyst consensus estimate of $8.56 million by 21.47 percent. This is a 28.97 percent increase over sales of $5.21 million the same period last year.